Bristol Myers, Abecma and 2seventy
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval in April.
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
Shares of 2seventy bio (NASDAQ:TSVT) lost ~16% in the premarket Wednesday after the cancer drug developer and its partner Bristol Myers Squibb (NYSE:BMY) announced plans to discontinue enrollment in an ongoing Phase 3 trial for their T cell immunotherapy,
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line myeloma
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial in first-line myeloma after struggling to enroll patients.
BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial
Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2
2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick Facts
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment
Buy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
Business Wire2d
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
BioPharma Dive2d
Struggling 2Seventy scraps a key cancer study
The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.
The Pharma Letter2d
2seventy bio and BMS to drop KarMMa-9 study
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
Hold Rating on 2seventy bio Amidst Strategic Shifts and Enrollment Challenges
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...
bovnews1d
TSVT’s Recent Drop: What’s Causing the Decline?
On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...
MarketWatch3d
2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
2seventy Bio stops enrolling patients in blood cancer therapy study
(Reuters) - 2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly ...